Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update- Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new drug application, and GV023, an oral formulation of an approved anti-TNF antibody -- FDA has stated in writing that additional clinical studies do not appear to be necessary to define the prophylactic dosing window for GV104, placing the critical path in manufacturing rather than in new clinical work -- Transaction creates a three-program portfolio spanning therapeutics and diagnostics, and Hepion intends to advance its circulating tumor RNA diagnostic toward a laboratory-developed test in 2027 -
